KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Neogenomics (NEO) EBIAT: 2009-2025

Historic EBIAT for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to -$27.1 million.

  • Neogenomics' EBIAT fell 53.28% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.5 million, marking a year-over-year decrease of 45.98%. This contributed to the annual value of -$78.7 million for FY2024, which is 10.51% up from last year.
  • Latest data reveals that Neogenomics reported EBIAT of -$27.1 million as of Q3 2025, which was up 39.84% from -$45.1 million recorded in Q2 2025.
  • In the past 5 years, Neogenomics' EBIAT ranged from a high of $75.9 million in Q2 2021 and a low of -$49.4 million during Q1 2022.
  • In the last 3 years, Neogenomics' EBIAT had a median value of -$24.3 million in 2023 and averaged -$24.1 million.
  • Within the past 5 years, the most significant YoY rise in Neogenomics' EBIAT was 1,211.86% (2021), while the steepest drop was 895.78% (2021).
  • Over the past 5 years, Neogenomics' EBIAT (Quarterly) stood at -$41.8 million in 2021, then surged by 45.67% to -$22.7 million in 2022, then skyrocketed by 36.85% to -$14.3 million in 2023, then dropped by 6.97% to -$15.3 million in 2024, then tumbled by 53.28% to -$27.1 million in 2025.
  • Its EBIAT was -$27.1 million in Q3 2025, compared to -$45.1 million in Q2 2025 and -$25.9 million in Q1 2025.